fashion -WSS

fashion

author：Wikipedia 2025-09-28 00:48:57 - browse：12

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Stanford president's case begs question: Who takes blame?

hotspot

leisure time

WSS

Patients, doctors are clashing about side effects of hormonal birth control

Senate panel passes drug pricing bills, but drops one PBM reform

Texas Department of Public Safety speaks out on migrant abuse allegations

Biden administration plans revamp of organ transplant system

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Alkermes shareholders re

7 more heat

How to save PrEP access — and even expand it

Hospitals struggle to profit from CAR

What does generative AI mean for health care? We asked experts

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Hepatitis C has a cure — but many Americans still lack access to it

Indian pharmaceutical industry in denial over drug

Malaria cases in Florida and Texas: Here’s what you need to know

Stanford president faces new allegations over 1999 paper

focus

EF3 tornado rips through North Carolina amid extreme weather nationwide

DeSantis talks Trump, trans issues and 'what wokeness is'

Ending racial health disparities hinges on penalties, political will

Divers poised to search for children washed away in Pennsylvania flash flood

Driven by the pandemic, applicants flood public health schools

Inside the rise of 'mukbang' eating videos

focus

explore

leisure time

knowledge